Siemens Healthineers Core Businesses Offset Currency, Tariff Challenges
By Billy Gray
Siemens Healthineers said fiscal first-quarter revenue grew on a comparable basis as results in its core business units, imaging and precision therapy, offset currency and tariff challenges.
The German healthcare company on Thursday posted 5.40 billion euros ($6.38 billion) in revenue for the first quarter through Dec. 31, down from 5.48 billion euros on year but up 3.8% on a comparable basis. Net profit for the quarter was 449 million euros compared with 474 million euros in the prior-year period, it said.
Analysts had expected a net profit of 418 million euros and revenue of 5.44 billion euros, according to estimates compiled by Vara Research.
Adjusted earnings before interest and taxes fell to 809 million euros from 822 million euros, while the margin for that metric stayed flat at 15.0%.
The company backed its 2026 guidance of comparable revenue growth of between 5% to 6% over fiscal 2025, and adjusted basic earnings per share in the range of 2.20 to 2.40 euros.
Write to Billy Gray at william.gray@wsj.com
(END) Dow Jones Newswires
February 05, 2026 01:38 ET (06:38 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States